At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study
In Brief
A clinical study evaluating Pravastatin and Lisinopril for HIV Infection and Cardiovascular Disease Risk. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection. Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces risk for heart disease in persons who are at increased risk (such as the case with HIV infection). Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure medication (or a placebo), and will be seen at 3 study visits over 4 months.
Study Details
Timeline
Interventions
Participants randomized to take pravastatin (active) or matching placebo pill once daily
Participants randomized to take lisinopril (active) or matching placebo pill once daily